Search Results

Risk of major cardiovascular events, severe hypoglycaemia, and all-cause mortality for users of insulin degludec versus insulin glargine U100-A Danish cohort study.

• Authors : Jensen MH; Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark.; Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.

Subjects: Cardiovascular Diseases/Cardiovascular Diseases/Cardiovascular Diseases/*mortality ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Hypoglycemia/Hypoglycemia/Hypoglycemia/*mortality

• Source: Diabetes/metabolism research and reviews [Diabetes Metab Res Rev] 2020 Jan; Vol. 36 (1), pp. e3225. Date of Electronic Publication: 2019 Nov 19.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883450 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

U.S. Clinical Trial: Novo Nordisk A/S Listed a New Clinical Trial to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes.

• Source: Contify Life Science News. 2024.

Record details

U.S. Clinical Trial: Novo Nordisk A/S Listed a New Clinical Trial to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4) (COMBINE 4).

• Source: Contify Life Science News. 2024.

Record details

COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes.

• Source: Chemical Business Newsbase. 2024.

Record details

COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes.

• Source: European Union News. 2024.

Record details

Novo Nordisk Listed a New Clinical Trial to Study Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE).

• Source: Contify Life Science News. 2022.

Record details

Novo Nordisk achieves primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin glargine U100 in ONWARDS 1.

• Source: Chemical Business Newsbase. 2022.

Record details

Novo Nordisk achieves primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin glargine U100 in ONWARDS 1.

• Source: Contify Life Science News. 2022.

Record details

Novo Nordisk Listed a New Clinical Trial to Study Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4).

• Source: Contify Life Science News. 2021.

Record details

Investigational, once-weekly insulin icodec showed comparable efficacy and safety to once-daily insulin glargine U100 in phase 2 trial.

• Source: Plus Company Updates. 2020.

Record details